KRAS mutations occur in approximately 20% of all human cancers and are particularly prevalent in pancreatic ductal adenocarcinoma (PDAC, ~90%), non-small cell lung cancer (NSCLC, ~25%) and colorectal cancer (~40%) [1]. Here, KRAS is linked to cancer.